title: Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.
abstract: BACKGROUND
  The efficacy and benefit of second-line chemotherapy in advanced pancreatic adenocarcinoma has never been demonstrated although it is regularly used.
  
  
  METHODS
  A randomized phase II study evaluating oxaliplatin alone (OXA), infusional 5-fluorouracil alone (5-FU) and an oxaliplatin/infusional 5-FU combination (OXFU) in untreated advanced pancreatic adenocarcinoma has been conducted. In this trial, a second-line treatment with the OXFU regimen (OXA 130 mg/m2 2-h intravenous (i.v.) infusion combined with 5-FU (1000 mg/m2/day, continuous i.v., days 1-4), every 3 weeks) was offered to patients progressing after single agent treatment.
  
  
  RESULTS
  Eighteen out of 32 patients (12 males, median age 57 years) treated in the single agent arms received the OXFU combination in second-line treatment. WHO performance status was at least 2 in 61% of the patients. There was no objective response and 3 patients (17%) had a disease stabilisation. Median time to progression from the start of second-line treatment was 0.9 months. Median overall survival was 4.9 months from the start of front-line therapy and 1.3 months from the start of second-line therapy.
  
  
  CONCLUSIONS
  The results of this trial bring arguments to support a modest value of second-line chemotherapy for advanced pancreatic adenocarcinoma.
authors.affiliation: CHU Ambroise Paré, Boulogne. emmanuel.mitry@apr.aphp.fr
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Mitry
authors.forename: Michel
authors.initials: M
authors.lastname: Ducreux
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Ould-Kaci
authors.forename: Valérie
authors.initials: V
authors.lastname: Boige
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Seitz
authors.forename: Roland
authors.initials: R
authors.lastname: Bugat
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Breau
authors.forename: Olivier
authors.initials: O
authors.lastname: Bouché
authors.forename: Pierre-Luc
authors.initials: PL
authors.lastname: Etienne
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Tigaud
authors.forename: François
authors.initials: F
authors.lastname: Morvan
authors.forename: Esteban
authors.initials: E
authors.lastname: Cvitkovic
authors.forename: Philippe
authors.initials: P
authors.lastname: Rougier
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil